Cantor Fitzgerald assumed coverage of GH Research (GHRS) with an Overweight rating and $25 price target Data generated for psychedelics across a number of mental health disorders have been “transformational,” and the unmet need is “enormous” and growing, the analyst tells investors in a research note. The firm says sees the psychedelic total addressable market ultimately reaching $50B per year, which would be roughly 1M-1.5M patients treated per year, still only modest penetration, and believes there is room for plenty of successful options and companies offering psilocybin and novel synthetic products.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GHRS:
- GH Research to Present at ASCP Meeting on Breakthrough Depression Treatment
- GH Research to Present at ASCP Meeting on Depression Treatments
- GH Research Showcases Promising Depression Treatment Data at ASCP Meeting
- GH Research announces acceptance of presentation at ASCP
- GH Research: Promising Clinical Results and Strong Financial Position Justify Buy Rating
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue